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Abstract
Purpose We investigated the impact of promoter meth-
ylation on APC protein expression in patients with
hepatocellular carcinoma (HCC).
Materials and methods 50 patients [HCC (n=19), liver
metastasis (n=19), cholangiocellular cancer (n=7), and
benign liver tumors (n=5)] were studied for methylation
using Methylight analysis. APC mutation was investigated
by protein truncation test and direct sequencing of genomic
DNA. The protein expression was evaluated by immuno-
histochemistry and Western blot analysis.
Results The APC promoter was hypermethylated in
81.8% of non-cancerous liver tissue samples. All HCC
samples and ten patients with liver metastasis (52.6%)
exhibited APC promoter methylation. The degree of
methylation was signiﬁcantly higher in samples from HCC
compared to the non-cancerous liver tissue samples (63.1%
vs. 24.98%; p=0.001). The level of APC protein expression
was signiﬁcantly reduced in HCC samples compared to
that of the corresponding non-tumor liver tissue (p\0.05).
Conclusions PromotermethylationoftheAPCgeneseems
to be of signiﬁcance in hepatocarcinogenesis and results in
reduced protein expression in HCC. Interestingly, APC
promoter methylation is also present in the vast majority of
non-cancerous liver tissue whose (patho)physiological
function remains unresolved.
Keywords Promoter methylation   APC  
Methylight assay   Protein   Hepatocellular carcinoma
Introduction
Hepatocellular carcinoma (HCC) is the most prevalent pri-
marylivercancerandranksastheﬁfthmostcommoncancer
in the world, and the third most common cause of cancer-
related death (Bosch et al. 1999). More than 500,000 new
cases are diagnosed annually, with an age-adjusted world-
wide incidence of 5.5–14.9 per 100,000 population (Llovet
et al. 2003). The pathogenesis of HCC is multifactorial.
Environmental, infectious, nutritional, metabolic, and
endocrine factors contribute directly or indirectly to he-
patocarcinogenesis. The importance of individual factors
varies geographically depending on environmental and
socioeconomic inﬂuences. Synchronous occurrence of dif-
ferent risk factors, such as chronic viral hepatitis and
aﬂatoxinburdenorironoverloadinasinglepatientorpatient
populationincreasestheriskofdevelopingHCC.Apartfrom
genomic alterations, epigenetic changes such as promoter
methylation, may also contribute to hepatocarcinogenesis.
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DOI 10.1007/s00432-007-0321-yMethylation of DNA is a naturally occurring process
and involves covalent addition of a methyl group to the 50-
position of the cytosine ring followed by a guanine
nucleotide (CpG site) (Bird 1992). Small regions of
genomic DNA, called CpG islands, are often located in the
promoter region of genes and are usually unmethylated in
normal tissue. These regions can be methylated under
pathological conditions such as tumor formation. Evidence
is increasing that aberrant DNA methylation participates
even in the early and precancerous stages of human
carcinogenesis.
The adenomatous polyposis coli (APC) tumor suppres-
sor gene encodes a large protein with multiple cellular
functions and interactions, including signal transduction in
the Wnt-signaling pathway. Preliminary reports suggest
that the APC promoter is methylated in up to 81% of
patients with viral hepatitis-induced HCC using the meth-
ylation-speciﬁc polymerase chain reaction (MSP) (Lee
et al. 2003; Yang et al. 2003). Inasmuch as the APC pro-
moter has two major promoters (1A and 1B) with ﬁve
alternatively spliced 50 untranslated regions in different
transcripts, so far various groups have reported only
methylation of the 1A promoter, while the 1B promoter has
not been shown to be affected by hypermethylation (Tsu-
chiya et al. 2000; Esteller et al. 2000; Zysman et al. 2002).
To date, however, APC protein expression has not been
evaluated in these patients. Therefore, we investigated the
impact of promoter methylation of the APC 1A gene pro-
moter on the corresponding protein levels in patients with
HCC.
Materials and methods
Patients
Tissue samples used in the present study were available
from 50 patients who had undergone liver resection. The
age of the 19 patients (15 men, 4 women) diagnosed with
HCC ranged from 51 to 77 years (mean 67.1 ± 7.2 years).
Tissue samples from patients with HCC and corresponding
non-neoplastic liver parenchyma had been obtained after
surgery (mean tumor size 7.95 ± 5.2 cm). The HCCs were
categorized according to differentiation into well (G1;
three cases), moderately (G2; eleven cases), or poorly (G3;
ﬁve cases) differentiated types, which correspond, respec-
tively, to Edmondson’s Grades I/II, III, or IV (MacSween
et al. 2002). In eight males patients, a regular alcohol
intake of more than 60 g/day over a period of 5 years was
documented. One patient was diagnosed as having hered-
itary hemochromatosis. In two cases a positive serology for
the core protein of hepatitis B virus (HBV) (‘‘anti-HBc
antibody alone’’) was found without evidence of viral
replication. Serological studies for hepatitis C virus (HCV)
remained negative in all patients. Ten patients had cryp-
togenic HCC (Table 1). Locally advanced disease was
found in four cases at time of liver resection. Alpha feto-
protein (AFP) serum level was available from all patients,
ranging from 1.3 to 95,468 ng/ml. In eight patients AFP
level remained normal during follow-up. Histologically, an
advanced liver ﬁbrosis (Ishak’s ﬁbrosis scores 3 and 4) or
liver cirrhosis (Ishak’s ﬁbrosis scores 5 and 6) (Ishak et al.
1995) was diagnosed in 12 patients in the corresponding
non-tumor tissue.
Tissue samples were also obtained by surgical resection
from 19 patients (8 men, 11 women) with liver metastases
[colorectal (n = 15), gastric (n = 1), renal (n = 1), and
breast (n = 2) cancer]. The age of patients ranged from 32
to 82 years (mean 63.5 ± 14.2 years). The liver metastases
were also categorized according to differentiation into well
(G1; no case), moderately (G2; ﬁfteen cases), or poorly
(G3; four cases) differentiated carcinomas. Tissue samples
were also obtained from seven patients with bile duct
(n = 5) or gall bladder cancer (n = 2): (G1; one case),
moderately (G2; four cases), or poorly (G3; two cases).
The age of patients ranged from 42 to 71 years (mean
57.4 ± 12.2 years). Five patients (mean age
40.4 ± 14.6 years) with benign liver tumors [focal nodular
hyperplasia (n = 4) or liver adenoma (n = 1)] were also
investigated (Table 2). Corresponding non-tumorous liver
parenchyma, as conﬁrmed histologically, was also evalu-
ated in all non-HCC cases. This study was approved by the
Ethics Committee of the Otto-von-Guericke University of
Magdeburg.
DNA extraction
Genomic DNA was extracted from frozen tissue samples
using the proteinase K digestion as previously reported
(Ebert et al. 2003).
Sodium bisulﬁte modiﬁcation
Five lg of genomic DNA was heat-denatured for 6 min at
97C, followed by incubation with 0.2 mol/l NaOH for
10 min at room temperature. The denatured DNA was
treated with 3.5 mol/l sodium bisulﬁte and 1 mmol/l
hydroquinone (pH 5.0) for 16 h at 55C. The reaction
mixture was puriﬁed with a gel extraction kit, and desul-
fhonated with 0.3 mol/l NaOH for 10 min at room
temperature. The DNA was then precipitated with three
volumes of cold ethanol, dissolved in H2O, and stored at
-20C.
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123Methylight analysis of the APC gene
Genomic DNA of all samples was analyzed by the
Methylight technique after bisulﬁte conversion as previ-
ously reported (Eads et al. 2000). In this analysis three
oligonucleotids were used in every reactions. Two locus-
speciﬁc PCR primers ﬂanked an oligonucleotide probe with
a5 0 ﬂuorescent reported dye (6FAM) and a 30 quencher dye
(BHQ-1). Oligonucleotide primers and probes were spe-
ciﬁcally designed to bind to bisulﬁte-converted DNA. The
gene of interest was then ampliﬁed and normalized to a
reference set (b-actin = ACTB) to normalize for input
DNA. The speciﬁcity of the reactions for methylated DNA
is conﬁrmed using human unmethylated sperm DNA and
CpGenome Universal Methylated DNA [(Chemicon (sub-
sidiary or Serologicals) catalog no. S7821)]. TaqMan PCR
reactions were performed in parallel with primers speciﬁc
for the bisulﬁte-converted methylated sequence for a par-
ticular locus and with the ACTB reference primers. The
ratio between the values was calculated in these two
TaqMan analyses. The extent of methylation at a speciﬁc
locus was determined by the following formula:
gene/actb ðÞ
sample : gene/actb ðÞ
SssI treatedgenomicDNA
hi
  100.
A cut-off value of 4% gave the best discrimination between
normal and cancerous samples, as previously reported in
esophageal cancer (Eads et al. 2000). In our study, samples
with a percentage of methylation reference (PMR) of C4%
fully methylated molecules were termed methylated,
whereas samples with a PMR of \4% were considered
unmethylated. The primer and probe sequences for APC
promoter 1A (GeneBank accession number U02509,
Fig. 1) were: forward primer (50–30): GAACCAAAACGC
TCCCCAT; reverse primer (50–30): TTATATGT CGGTT
ACGTGCGTTTATAT; probe sequence (50–30): 6FAM-
CCCGTCGAAAAC CCGCCGATTA-BHQ1 were used as
previously reported (Eads et al. 2000).
Mutation analysis of the APC gene
The mutation cluster region of the APC was analyzed by a
non-radioactive protein truncation test (PTT) in 12 patients
with HCC as previously described (Kahmann et al. 2002).
Brieﬂy, the region was ampliﬁed by PCR from the genomic
DNA in two overlapping fragments. The used primers
include the sequence motifs, which are necessary for the in
vitro transcription and translation, and the sequences,
which code for the haemagglutinin (HA) protein motif,
which serves as an immuno-tag in the following Western
blot detection. The PCR results in two overlapping prod-
ucts: APC I corresponding to sequence position 3283
through 4683 (codon 1089 through 1555) and APC II
corresponding to sequence position 4573 through 5970
(codon 1515 through 1984) of the APC gene. Next, the
PCR fragments were transcribed and translated in a one-
tube reaction by using commercial reagents and following
the protocol of the supplier (Promega, Mannheim,
Germany). The reaction products were separated by elec-
trophoresis on a 12.5% SDS-polyacrylamide gel and
electroblotted. The membrane was incubated with mono-
clonal anti-HA tag antibody as the ﬁrst and HRP-coupled
goat-anti mouse antibody as the second antibody. Detection
was performed by enhanced chemoluminescence (ECL)
using commercial reagents. All primer sequences and the
exact conditions for PCR and the in vitro transcription and
translation are available upon request.
Western blot analysis
Frozen tissue from non-tumorous liver parenchyma and
HCC obtained from three patients were homogenized in
lysis buffer containing 1 mM EDTA, 50 mM b-glycero-
phosphate, 2 mM sodium orthovanadate, 1% Triton-100,
10% glycerol, 1 mM DTT, and protease inhibitors (10 mg/
ml benzamidine, 2 mg/ml anti-pain, and 1 mg/ml leupep-
tin). The protein concentration of the supernatants was
determined by the BCA assay (Bio-Rad, Hercules, CA,
USA). Twenty micrograms of protein in each sample was
adjusted to Laemmli buffer [2% SDS, 10% glycerol,
62.5 mM Tris–HCl (pH 6.8), 100 mM DTT, and 0.1%
bromphenol blue], denatured by heating at 95C for 5 min,
and subsequently separated on 5% polyacrylamide gels by
SDS-gel electrophoresis. After separation, the proteins were
transferred onto immunoblot polyvinylidene diﬂuoride
t c t c a t t a t tc t c c a c c c t c c c G C a t c c c a t c t t c c t a a t c a t a t t c t a c a G C c c c c t c c a a G C a t a t c a t t t c t c a G C t t c a t t c c t t c a a c t a c c a t c a a c t a t
c a a a a t c a a a a a t c a G C G C c c c c a t a c a a a a G C a t a a a a a G C a t a t c a a a c a a a t c a a a a t c a a a G C a a a t t a G C a t c a c c c c a t a t c c c a a a C
G a t a a a G C t a a G C a a a a a G C c t a a t a t a t c a a c a a a a a a a a a a G C a t a a a t c t a c c c c t c G C a a a a c c a a G C t G C c c a a a a G C t G C c c
a t t a G C c a a t c a a a t a t a c a G C c a a t G C a c G C a a a t a t a c c a a c a t a a t t a t a t c G C a a a a a t c a c t a t a a a a c c c a t c a t a a a a a t a a a a c G C a
t c a G C t a a a t a a a a t a a a aa t a c c a c c a a a a t c a a t c a t t c a a a c c a G C t c c c t t t t a a t a a a a a a a a a a a a a a a a G C c a a a t t c t a t c a c G C t t t c c a a t a
c c t a a a a c a c a a t t c c a a a c c a t a c a a c a t c a G C a a a a a c a a a a a a
Fig. 1 Sequence of the APC 1A Promoter. A portion of bisulﬁte reverse complement strand of the APC gene promoter (NM_000038) is given
with the primer and probe location which were used for the Methylight analysis (underlined and bold). CpG sites are highlighted
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123membrane (Bio-Rad). The membrane was blocked in 5%
skimmed milk in 1% TBST for 1 h at room temperature,
and then incubated separately with anti-APC-N15 antibody
or anti-APC-C20 antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) overnight at 4C (dilution 1:200).
These two antibodies react with the N-terminal and C-ter-
minal part of the human APC protein, respectively.
Membranes were then washed three times in Tris-buffered
saline/0.1% Tween 20, incubated for 2 h with peroxidase-
labeled anti-rabbit IgG (1:2,500, KPL) and diluted in
blocking solution. Membrane-bound secondary antibodies
were detected by an enhanced chemiluminescence method
following the instructions of the manufacturer (ECL plus
Western blotting detection reagents, Amersham Biosci-
ences, Piscataway, NJ, USA). The membrane images were
evaluated for the quantiﬁcation of the protein expression,
using the GeneGnome and GeneTools image scanning and
analysis package (Syngene BioImaging Systems, Synoptics
Ltd., Frederick, MD, USA).
Immunohistochemistry
Tissue samples from HCCs and corresponding non-
neoplastic liver parenchyma were studied by immunohis-
tochemistry. Deparafﬁnized sections were stained using
hematoxylin and eosin (H&E). For immunostaining of
parafﬁn-embedded sections, the slides were deparafﬁnized
in xylol and rehydrated in a graded alcohol series.
Endogenous biotin was blocked using the Avidin/Biotin
Blocking kit (2 9 15 min; Vector Laboratories Inc., Bur-
lingame, CA, USA). Immunostaining was performed with
two antibodies directed against human APC (rabbit-anti-
APC-N15, dilution 1:200; rabbit-anti-APC-C20, dilution
1:20). Incubation with the primary antibodies was per-
formed in a moist chamber at 37C for 1 h. Gout anti-
rabbit IgG (30 min, room temperature; Vector Laboratories
Inc.) served as a secondary antibody. Slides were washed
between steps with Tris-buffered saline. Immunoreactions
were visualized via an streptavidin-biotin complex, using
the Vectastain ABC alkaline phosphatase kit (distributed
by CAMON, Wiesbaden, Germany). FastRed (Zytomed,
Berlin, Germany) served as chromogen. The specimens
were counter-stained with hematoxylin. Omission of pri-
mary antibodies served as a negative control.
Immunoreactivity score (IRS)
For the quantiﬁcation of the immunohistochemical results,
a numerical scoring system was applied. The observed
expression of APC in hepatocytes and tumor cells was
assessed using two categories. Category A documented the
number of immunoreactive epithelial cells as 0 (no
immunoreactive cells), 1 (\10%), 2 (11–50%), and 3
([50%). A positive case was deﬁned as having a category
A value of 1. Category B documented the intensity of the
immunostaining as 0 (no immunostaining), 1 (weak), 2
(moderate), and 3 (strong). Finally, the values for category
A and B were added to construct an ‘‘immunoreactivity
score’’ (IRS), which could range from 0 to 6. Note that the
method of calculating the IRS does not allow the individual
categories to add up to an IRS of 1. The immunostaining
was performed and analyzed by an experienced GI
pathologist (CR) who was blinded to the methylation status
of the APC gene.
Statistical analysis
The PMR values of the Methylight assays were dichoto-
mized for statistical purposes as reported previously (Eads
et al. 2000). The PMR values of tumor and non-tumor
samples were compared by Kolmogorov–Smirnov test, and
a P\0.05 was considered statistically signiﬁcant.
Results
APC promoter methylation in liver cancer
Using the Methylight assay, the methylation status of the
1A APC promoter was evaluated in 19 HCCs and the
corresponding non-tumor liver samples. All patients with
HCC and 15 of the 19 non-tumorous liver samples (79%)
exhibited a PMR[4%. The mean PMR was 63.10 (range
from 23.41 to 100) in the HCC and 14.19 (range from 0 to
39.92) in the non-tumor samples (Table 1). The difference
between tumor and non-cancerous samples was statistically
signiﬁcant (P = 0.001). Even after extraction of the non-
tumor samples with a PMR\4% which were classiﬁed as
not methylated, the degree of methylation in HCC was
signiﬁcantly higher compared to the non-cancerous tissue
samples (63.1% vs. 25.12%; P = 0.001). There was no
difference between cirrhotic and non-cirrhotic samples
regarding AFP levels, degree of methylation or protein
expression evaluated by immunohistochemistry (Table 1).
No correlation was found between the size and differenti-
ation of HCC and AFP level, grade of ﬁbrosis or presence
of metastasis. Also, the grade of promoter methylation was
not signiﬁcantly different in samples from patients with
large tumor or liver cirrhosis compared to those samples
obtained from smaller cancers or patients without advanced
liver ﬁbrosis (Table 1).
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We then assessed the frequency of APC promoter meth-
ylation in 19 liver metastases and compared it to the
corresponding non-tumor liver samples (Table 2). Our
analysis showed promoter methylation in eight metastases
of colorectal cancers (50%), in one gastric and one breast
cancer metastasis. Altogether, 52.6% of metastatic tissue
samples were found to be hypermethylated. About 17 of
the 19 non-tumor liver samples (89.5%) also showed pro-
moter hypermethylation. The mean PMR was 21.19 (range
0–45.51) in the liver metastases and 15.41 (range 0–69.95)
in the non-tumor tissue samples. Next, we assessed the
frequency of promoter hypermethylation of the APC gene
Table 2 Molecular results and characteristics of patients with other liver tumors
Patient Liver disease/
primary cancer
Non-tumor tissue Tumor tissue
Fibrosis score
(Ishak et al. 1995)
Methylight analysis Differentiation
(MacSween et al. 2002)
Methylight analysis
Result PMR (%) Result PMR (%)
Cholangiocellular carcinoma (CCC)
Case number
CCC1 Bile duct 6 Negative 2.57 G2 Negative 0
CCC2 Bile duct 0 Positive 21.74 G3 Negative 0
CCC3 Bile duct 2 Positive 5.82 G3 Negative 0
CCC4 Bile duct 0 Positive 16.97 G2 Positive 5.38
CCC5 Bile duct 0 Positive 24.38 G2 Negative 0
CCC6 Gall baldder 1 Negative 0 G1 Negative 0
CCC7 Gall bladder 0 Negative 0 G2 Negative 0
Liver metastasis (M)
Case number
M1 Breast 0 Positive 9.54 G2 Negative 0
M2 Colorectal 0 Positive 27.38 G2 Negative 0
M3 Colorectal 0 Positive 40.77 G3 Negative 0
M4 Colorectal 0 Positive 26.26 G3 Negative 0
M5 Nephroblastoma 0 Positive 6.71 G2 Negative 0
M6 Colorectal 0 Positive 20.91 G3 Positive 6.36
M7 Colorectal 4 Positive 5.46 G2 Negative 0
M8 Colorectal 0 Positive 18.23 G2 Negative 2.39
M9 Colorectal 0 Positive 45.51 G2 Positive 69.95
M10 Colorectal 0 Negative 0 G2 Positive 23.65
M11 Gastric 0 Positive 36.68 G3 Positive 23.74
M12 Colorectal 0 Positive 25.78 G2 Positive 21.65
M13 Colorectal 0 Positive 12.48 G2 Negative 0
M14 Colorectal 1 Positive 22.17 G2 Positive 27.73
M15 Colorectal 0 Positive 29.5 G2 Positive 57.92
M16 Colorectal 0 Positive 16.95 G2 Negative 0
M17 Breast 0 Positive 15.85 G2 Positive 30.51
M18 Colorectal 0 Positive 42.59 G3 Positive 21.44
M19 Colorectal 0 Negative 0 G2 Positive 7.57
Benign liver tumor (B)
Case number
B1 FNH 0 Negative 3.52 na Positive 24.09
B2 FNH 0 Positive 42 na Positive 69.82
B3 FNH 0 Positive 20.6 na Positive 67.29
B4 FNH 0 Positive 27.96 na Positive 15.24
B5 Hepatic adenoma 0 Positive 30.13 na Positive 79.45
FNH focal nodular hyperplasia
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123in seven patients with cholangiocarcinoma and found only
one tumor with methylated promoter. Four of the seven
non-tumor liver samples (57.2%) also showed promoter
hypermethylation (Table 2). The mean PMR was 10.27
(range 0–24.38) in the non-tumor tissue samples. Nine of
the ten tissue samples obtained from patients with benign
liver tumors were found to be hypermethylated with a
mean PMR of 38.01 (range from 3.52 to 79.45). Alto-
gether, 45 of the 55 non-cancerous liver samples (including
also those lesional and extralesional samples obtained from
patients with benign liver tumors) exhibited a PMR [4%
which results in an overall 81.8% hypermethylation rate.
The degree of methylation was signiﬁcantly higher in
samples from HCC compared to the non-cancerous liver
tissue samples (63.10% vs. 24.98%; P = 0.001). Using an
arbitrarily given PMR of 10%, 67% of non-cancerous liver
samples were methylated, and using a PMR of 20 and 30%,
only 47 and 20% of the 55 non-tumor tissues exhibited
APC promoter methylation. Of particular interest was that
all HCC samples exhibited a very high PMR above 20%.
We found no association of APC methylation levels and
age in any of the cancer patients in either tumor or non-
tumor tissues.
APC mutation analysis
The mutation cluster region of the APC gene was ampliﬁed
in two overlapping fragments. The PCR reactions led to
products of the expected sizes in 11 of the 12 genomic
DNAs (not shown). Sample 9 did not give any PCR
product. The PCR products were used as templates in the in
vitro transcription and translation reactions and the result-
ing proteins were analyzed by Western blot. All samples
showed the full-length proteins I and II of the expected size
of *55 kDa. Additionally, the analysis of protein II of
sample 4 showed fragments, which were *5–10 kDa
smaller than the full-length protein (Fig. 2). The PCR
fragment of the sample was cloned. All tested clones
showed truncated protein fragments in the PTT. Figure 3
shows the full length protein as a translation product of a
wild type control and four different clones. The sequencing
of the cloned fragments showed AGGGAT instead of the
wildtype sequence AGGAAT (Fig. 4). The A to G transi-
tion was found in all tested clones by forward and reverse
sequencing. The mutation leads to an alteration of the
amino acid Glu to Gly at codon 1889 of the APC protein.
Fig. 2 Western blot of the PTT analysis of the APC protein fragment
II (aa1519 through aa1984). The sizes of corresponding marker
fragments are shown on the left in kilodaltons. The full-length protein
(ﬂAPC II) and the mutated shortened protein (trAPC II) are indicated
on the right. WT protein, which was obtained by PTT analysis of non-
mutated wild-type DNA, C DNA free control sample
Fig. 3 PTT analysis of four different clones of sample 4 in Fig. 2.
The sizes of corresponding marker fragments are shown on the left in
kilodaltons. The full-length protein (ﬂAPCII) and the mutated
shortened protein (trAPCII) are indicated on the right. All clones
show truncated proteins in addition to full length protein. WT protein,
which was translated in vitro from non-mutated wild-type DNA
Fig. 4 Sequencing results of the APC gene from sample 4. Upper
panel: chromatogram from forward sequencing and blast of the APC
gene sequence (GenBank, accession number M74088) using the blast
software (http://www.ncbi.nlm.nih.gov/BLAST/). The mutated
nucleotide and amino acid are shown in bold. Lower panel: results
from reverse sequencing
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123Detection of APC protein expression in HCC and liver
metastasis
Next we investigated the APC protein expression in both
tumor and corresponding non-neoplastic tissue samples
obtained from patients with HCC (Fig. 5). By Western blot
analysis two isoforms of the APC protein (200 and
300 kDa, respectively) were identiﬁed. We observed no
quantitative differences in APC proteins levels in tumor
and non-tumor samples.
Immunohistochemical analysis of APC expression
Immunohistochemistry was performed on parafﬁn-embed-
ded sections from 14 patients with HCC. APC was found in
the cytoplasm of each of the hepatocytes of non-tumorous
liver parenchyma (14 patients), bile duct epithelium
(Hiltunen et al. 1997), vascular smooth muscle cells
(Hiltunen et al. 1997), and tumor cells (Behrens et al. 1998)
(Fig. 6). The intensity of immunostaining and the number
of immunoreactive cells were decreased in tumorous epi-
thelium of 12 patients, when compared with the
corresponding non-tumorous epithelium (Fig. 6). The
expression of APC was similar in tumorous and non-
tumorous epithelium of two patients. The difference
between tumor cells, and non-tumorous hepatocytes was
further quantiﬁed by determining the mean IRS values (±
standard deviation). The non-tumorous hepatocytes showed
a mean IRS with anti-APC-N15 of 4.5 ± 1.0, and with
anti-APC-C20 of 4.8 ± 0.6, while in HCCs tumor cells
showed a mean IRS with anti-APC-N15 of 3.0 ± 1.5, and
with anti-APC-C20 of 3.8 ± 1.2. These IRS values reﬂect
the overall signiﬁcantly reduced (P\0.05) expression of
APC in HCCs.
Discussion
The human APC gene product is part of a tetrameric
complex, composed of conductin, a negative regulator of
Wnt signaling, APC, GSK-3b (serine–threonine glycogen
synthase kinase 3b) and b-catenin (Behrens et al. 1998).
The intact APC protein normally exerts an anti-tumor
effect by forming a tetrameric complex, resulting in the
accelerated degradation of b-catenin and the inhibition of
signal transduction to the lympoid enhancer factor-T cell
factor (LEF-TCF) family of transcription factors. The
truncated or functionally inactive APC protein which can
result from (1) transcriptional silencing through promoter
methylation, (2) a point mutation of the APC gene or (3)
loss of heterozygosity (LOH) (Hiltunen et al. 1997; Chen
et al. 2005) loses the ability to interact with b-catenin,
allowing the direct interaction of b-catenin with LEF-TCF
family of transcription factors and promoting cells to enter
the cell cycle.
The clinical impact of transcriptional silencing of the
APC gene induced by promoter methylation in HCC is
currently unclear. A recent study showed that APC hy-
permethylation can disrupt the APC/b-catenin pathway in
primary liver cancer in one-third of the investigated cases
(Esteller et al. 2001). In contrast, in an earlier report from
China, the promoter region of the APC gene was found to
be free of methylation both in tumor and non-tumor tissue
samples obtained from patients with HBV-induced HCC
using the same MSP method as reported in the ﬁrst study
(Yu et al. 2002). More recently, three groups used MSP or
an MSP-based quantitative methylation analysis and
reported that the APC promoter is methylated in 53–85% of
patients with HCC (Lee et al. 2003; Yang et al. 2003;
Lehmann et al. 2005). A particularly high frequency of
promoter methylation was found in HCV- and HBV-related
HCCs affecting 80 and 55% of the cases, respectively (Lee
et al. 2003; Yang et al. 2003). The CpG islands of the APC
promoter were methylated in up to 27% of patients with
liver cirrhosis and in 14–32% of liver tissue samples
without any pathological changes (Lee et al. 2003; Yang
et al. 2003; Lehmann et al. 2005).
In our study, the MethyLight analysis, a novel method
for epigenetic studies was used. It provides a more sensi-
tive tool for detecting promoter methylation and also
allows quantitative assessment of methylation. We
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Fig. 5 a Western blot analysis of APC protein expression in three
normal (N) and tumor (T) tissue samples obtained from three patients
with hepatocellular carcinoma. Two isoforms of the APC protein (300
and 200 kDa, respectively) were observed using antibodies directed
against the APC protein. The sizes of corresponding marker
fragments are shown on the right in kilodaltons. b Quantitative
analysis of APC protein expression in hepatocellular cancer. The
levels of APC expression in cancer and non-cancer tissues (the order
of the patients is identical to the panel above) were standardized to the
respective beta-actin expression levels. Overall no signiﬁcant differ-
ence among the two isoforms was observed
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123demonstrate a high-methylation rate of the 1A APC pro-
moter: 81.8% of the non-cancerous liver tissue samples
exhibited a PMR [4%. Even when a signiﬁcantly higher
methylation rate of 20% was used, 47% of samples
remained methylated. The (patho) physiological function
and signiﬁcance of the methylated APC promoter in the
non-malignant liver tissue samples is unclear.
The APC promoter has also been reported to be meth-
ylated in normal breast tissue samples of women at high
risk for breast cancer in 56% of cases (Lewis et al. 2005).
About 97.5% of patients with non-cancerous gastric
mucosa also exhibited APC promoter methylation and this
was considered—in contrast to the colon (Chen et al.
2005)—a normal event (Tsuchiya et al. 2000). However,
the function and clinical signiﬁcance of the methylated
APC promoter in normal tissue and normal mucosa has not
been addressed in the past. The high frequency of APC
promoter methylation in non-cancerous liver parenchyma
as observed in our study may be explained in different
ways. (1) A low level of methylation of the APC promoter
occurs physiologically in the liver, and may have been
missed by previous investigation, simply because the
Methylight assay used herein is far more sensitive than the
MSP protocol applied by others (Eads et al. 2000); (2) APC
promoter methylation in non-tumorous liver parenchyma
may result from methylation ﬁeld effects in the chronically
inﬂamed, ﬁbrotic liver, which bears the risk of developing
HCC. Thus, APC promoter hypermethylation may precede
the development of histologically overt lesions, such as
dysplastic nodules, small cell dysplasia or HCC, none of
which were studied in our non-lesional tissue samples.
However, non-tumorous liver parenchyma without evi-
dence of chronic inﬂammation, ﬁbrosis or cirrhosis (in our
study samples obtained from patients with liver metastases)
showed APC promoter methylation which supports the ﬁrst
interpretation. Further studies are clearly needed to resolve
this very interesting issue in epigenetic studies.
The 1A promoter region of the APC gene was found to
be methylated in all tissue samples from patients with HCC
using the 4% PMR, and all samples remained methylated at
a PMR of 20%. Our ﬁndings indicate that the 1A APC
promoter is generally methylated in the liver suggesting
that this epigenetic change is not speciﬁc for hepatocarci-
nogenesis and is not related to chronic hepatitis virus
Fig. 6 Immunohistochemical
expression of APC in liver and
hepatocellular carcinomas. The
distribution and expression
pattern of APC in non-tumorous
liver and HCCs was
investigated by
immunohistochemistry. Non-
tumorous epithelium, and tumor
were stained with two different
anti-APC antibodies (anti-APC-
N15 and anti-APC-C20). APC
was found in the cytoplasm. In
the majority of the patients
studied, the intensity of
immunostaining and the number
of immunoreactive cells was
decreased in tumorous
epithelium (right) when
compared with the
corresponding non-tumorous
epithelium (left)
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123infection as reported in the previously published studies
(Lee et al. 2003; Yang et al. 2003), because all tissue
samples investigated in our study were obtained from
patients with non-hepatitis virus-related HCC. It was of
particular interest that the methylation grade of the APC
promoter was signiﬁcantly enhanced in the HCC samples
compared with that of the corresponding non-tumor
samples. These ﬁndings suggest that quantitative epige-
netic changes are probably of clinical signiﬁcance in
hepatocarcinogenesis, but further post-transcriptional
mechanisms must also be responsible for inactivation of
the APC gene in HCC.
While somatic APC gene mutations are prevalent in
some gastrointestinal tumors such as colorectal cancer
(Chen et al. 2005), HCC usually do not harbor APC
mutations. In our series, an APC mutation was found in
only one patient (8%). The mutation, however, which was
found and conﬁrmed in this sample did not cause a stop
codon and the sequencing results excluded non-sense or
frameshift mutations caused by the Taq polymerase. Nev-
ertheless, the detected transition might be the reason for the
truncated proteins which were detected in the PTT. A
mutation in a similar repetitive motif of the APC gene
reported by Laken et al. was shown to lead to truncated
proteins in the PTT in addition to the full length protein
(Laken et al. 1997). The authors explained this ﬁnding by
failures in the transcriptional or translational machinery
caused by the mutation. In summary, APC gene mutations
do not seem to play an important role in the inactivation of
APC in HCC.
Previous studies focused on epigenetic changes of the
APC promoter but did not evaluate the APC protein
expression in HCC (Lee et al. 2003; Yang et al. 2003;
Esteller et al. 2001; Yu et al. 2002). Therefore, in our
analysis, we assessed the impact of promoter methylation
of APC on protein expression in HCC and non-tumor tissue
samples. Using Western blot analysis, both isoforms of the
APC protein were shown to be present indicating that APC
protein is expressed in primary liver cancer cells. In order
to further evaluate subcellular expression of the APC
protein, immunohistochemistry with a numerical scoring
system allowing semiquantitative analysis of the expressed
protein was applied. The APC protein was expressed both
in non-tumor and tumor tissue samples obtained from
patients with HCC, but values derived from our IRS were
signiﬁcantly lower in HCC samples compared with that of
non-cancerous liver tissue samples. This ﬁnding reﬂects the
overall reduced expression of the APC protein in patients
with HCC.
In conclusion, using a highly sensitive tool for detecting
epigenetic changes, we demonstrate that APC promoter
methylation is a very frequent epigenetic change in patients
with HCC. Furthermore, we show that methylation of the
APC promoter is also present in the vast majority of the
non-tumorous liver tissue samples, indicating that this low
level of APC methylation is universally present in the liver
cells and is not a speciﬁc marker of liver carcinogenesis
and is probably not induced by hepatitis virus infection.
Because promoter methylation is signiﬁcantly enhanced in
HCC compared to that of non-tumor samples, and APC
expression is also signiﬁcantly reduced in liver cancer
cells, higher degrees of promoter methylation of the APC
gene seem to be responsible for the reduced APC protein
expression in HCC. The pathophysiological function of the
hypermethylated APC promoter in non-tumor liver cells
deserve further studies to resolve this important issue.
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